Amgen Past Earnings Performance
Past criteria checks 0/6
Amgen's earnings have been declining at an average annual rate of -8.2%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 5% per year. Amgen's return on equity is 56.2%, and it has net margins of 13%.
Key information
-8.2%
Earnings growth rate
-5.1%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 5.0% |
Return on equity | 56.2% |
Net Margin | 13.0% |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Amgen's (NASDAQ:AMGN) Problems Go Beyond Weak Profit
Nov 08Amgen: A Biotech Giant Offering Value And Growth In A Frothy Market
Nov 03Amgen Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year
Nov 02Amgen Q3 Earnings Review: So Many Questions, But MariTide Data Top Of The List
Oct 25Amgen: Pipeline Updates, Uplizna Performs And Rocatinlimab Underwhelms
Sep 26Amgen: Growth Is Still A Better Choice
Aug 28Amgen Inc. Just Missed EPS By 46%: Here's What Analysts Think Will Happen Next
Aug 09Amgen: Shows Why Dividend Investing Is Getting Tougher
Aug 07Amgen (NASDAQ:AMGN) Takes On Some Risk With Its Use Of Debt
Jul 26The Price Is Right For Amgen Inc. (NASDAQ:AMGN)
Jul 11Amgen: An Emerging GLP-1 Play, Modest Mid-Teens P/E With Strong Momentum
Jul 05Amgen: You Haven't Seen Anything Yet
Jun 17Amgen Is A Fantastic Dividend Growth Stock With A Weight-Loss Wild Card
Jun 04Amgen Stock: Poised To Break Out (Technical Analysis)
May 21Is Amgen Inc. (NASDAQ:AMGN) Trading At A 41% Discount?
May 04Amgen Stock: Recent Weakness Is Not A Buying Opportunity Yet
May 01Amgen: The Giant With An Impressive Pipeline
Apr 15Is Amgen (NASDAQ:AMGN) Using Too Much Debt?
Apr 01Move Over Eli Lilly: Amgen Could Be The Next Obesity Wonder Stock
Mar 31Amgen Will Benefit From Increased Medical Spending
Mar 12Amgen: A Good Dividend Growth Stock For The Watch List
Mar 04Amgen's (NASDAQ:AMGN) Shareholders May Want To Dig Deeper Than Statutory Profit
Feb 21Pinning Down Amgen Inc.'s (NASDAQ:AMGN) P/E Is Difficult Right Now
Feb 16Amgen: Weight Loss Drug Candidate Debate A Red Herring - Buying The Dip Advisable
Feb 08Amgen: Accelerating The Business And Dividend Growth
Jan 29Is Amgen Inc. (NASDAQ:AMGN) Trading At A 44% Discount?
Jan 29Up 40%, 3%-Yielding Amgen Is Still One Of My Favorite Healthcare Stocks
Jan 22Is Amgen (NASDAQ:AMGN) A Risky Investment?
Dec 28Here's Why Amgen (NASDAQ:AMGN) Has Caught The Eye Of Investors
Dec 13Are Investors Undervaluing Amgen Inc. (NASDAQ:AMGN) By 46%?
Oct 23Revenue & Expenses Breakdown
How Amgen makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 32,534 | 4,230 | 7,479 | 5,745 |
30 Jun 24 | 30,934 | 3,130 | 7,207 | 5,374 |
31 Mar 24 | 29,532 | 3,763 | 6,716 | 5,040 |
31 Dec 23 | 28,190 | 6,717 | 6,166 | 4,755 |
30 Sep 23 | 26,833 | 7,566 | 5,477 | 4,574 |
30 Jun 23 | 26,582 | 7,979 | 5,411 | 4,607 |
31 Mar 23 | 26,190 | 7,917 | 5,444 | 4,533 |
31 Dec 22 | 26,323 | 6,552 | 5,414 | 4,434 |
30 Sep 22 | 26,330 | 6,835 | 5,267 | 4,458 |
30 Jun 22 | 26,384 | 6,576 | 5,285 | 4,768 |
31 Mar 22 | 26,316 | 5,723 | 5,342 | 4,811 |
31 Dec 21 | 25,979 | 5,893 | 5,368 | 4,819 |
30 Sep 21 | 25,767 | 5,609 | 5,716 | 4,700 |
30 Jun 21 | 25,484 | 5,746 | 5,757 | 4,340 |
31 Mar 21 | 25,164 | 7,085 | 5,668 | 4,222 |
31 Dec 20 | 25,424 | 7,264 | 5,730 | 4,207 |
30 Sep 20 | 24,987 | 7,352 | 5,470 | 4,290 |
30 Jun 20 | 24,301 | 7,299 | 5,347 | 4,229 |
31 Mar 20 | 23,966 | 7,675 | 5,312 | 4,189 |
31 Dec 19 | 23,362 | 7,842 | 5,150 | 4,116 |
30 Sep 19 | 23,395 | 8,067 | 5,196 | 3,986 |
30 Jun 19 | 23,562 | 7,958 | 5,266 | 3,911 |
31 Mar 19 | 23,750 | 8,075 | 5,359 | 3,856 |
31 Dec 18 | 23,747 | 8,394 | 5,332 | 3,737 |
30 Sep 18 | 23,319 | 2,202 | 5,268 | 3,598 |
30 Jun 18 | 23,188 | 2,364 | 5,145 | 3,549 |
31 Mar 18 | 22,939 | 2,219 | 5,001 | 3,553 |
31 Dec 17 | 22,849 | 1,979 | 4,870 | 3,562 |
30 Sep 17 | 23,012 | 8,178 | 4,824 | 3,597 |
30 Jun 17 | 23,050 | 8,174 | 4,898 | 3,710 |
31 Mar 17 | 22,928 | 7,893 | 4,981 | 3,737 |
31 Dec 16 | 22,991 | 7,722 | 5,120 | 3,840 |
30 Sep 16 | 22,562 | 7,587 | 5,164 | 3,791 |
30 Jun 16 | 22,474 | 7,433 | 5,164 | 3,920 |
31 Mar 16 | 22,156 | 7,216 | 5,032 | 3,984 |
31 Dec 15 | 21,662 | 6,939 | 4,855 | 4,006 |
30 Sep 15 | 21,457 | 6,433 | 4,778 | 4,162 |
30 Jun 15 | 20,765 | 5,814 | 4,747 | 4,061 |
31 Mar 15 | 20,575 | 5,708 | 4,723 | 4,115 |
31 Dec 14 | 20,063 | 5,158 | 4,720 | 4,248 |
30 Sep 14 | 19,743 | 4,885 | 4,851 | 4,312 |
30 Jun 14 | 19,460 | 5,009 | 4,887 | 4,283 |
31 Mar 14 | 18,959 | 4,720 | 5,007 | 4,232 |
31 Dec 13 | 18,676 | 5,081 | 5,142 | 4,083 |
Quality Earnings: AMGN has a large one-off gain of $1.1B impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: AMGN's current net profit margins (13%) are lower than last year (28.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AMGN's earnings have declined by 8.2% per year over the past 5 years.
Accelerating Growth: AMGN's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: AMGN had negative earnings growth (-44.1%) over the past year, making it difficult to compare to the Biotechs industry average (16.6%).
Return on Equity
High ROE: Whilst AMGN's Return on Equity (56.2%) is outstanding, this metric is skewed due to their high level of debt.